In patients with relapsed or refractory classic Hodgkin lymphoma, pembrolizumab may be superior to brentuximab vedotin and provide statistically significant and clinically meaningful improvement in PFS across all subgroups.
In patients with relapsed or refractory classic Hodgkin lymphoma, pembrolizumab may be superior to brentuximab vedotin and provide statistically significant and clinically meaningful improvement in PFS across all subgroups.
In patients with relapsed or...